Surgery Partners Stock Performance
| SGRY Stock | USD 23.83 0.41 1.75% |
The entity has a beta of 2.28, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Surgery Partners will likely underperform. Surgery Partners has an expected return of -0.47%. Please make sure to validate Surgery Partners treynor ratio and daily balance of power , to decide if Surgery Partners performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Surgery Partners has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (4.29) | Five Day Return (9.05) | Year To Date Return (25.96) | Ten Year Return 23.26 | All Time Return 23.26 |
1 | Sale by Bradley Owens of 1040 shares of Surgery Partners | 02/14/2024 |
2 | Citi maintains Buy on Surgery Partners stock, expects EBITDA to hit estimates | 02/20/2024 |
3 | Company News for Feb 27, 2024 | 02/27/2024 |
4 | Disposition of 9070 shares by Evans Jason Eric of Surgery Partners at 30.61 subject to Rule 16b-3 | 03/04/2024 |
5 | Disposition of 1347 shares by Anthony Taparo of Surgery Partners at 30.7 subject to Rule 16b-3 | 03/05/2024 |
6 | Insider Sell CFO David Doherty Sells 3,426 Shares of Surgery Partners Inc | 03/07/2024 |
7 | Disposition of 651 shares by Anthony Taparo of Surgery Partners at 29.54 subject to Rule 16b-3 | 03/11/2024 |
8 | Disposition of 787 shares by Anthony Taparo of Surgery Partners at 29.87 subject to Rule 16b-3 | 03/12/2024 |
9 | Insider Sell CEO Jason Evans Sells 6,824 Shares of Surgery Partners Inc | 03/13/2024 |
10 | Disposition of 721 shares by David Doherty of Surgery Partners at 28.59 subject to Rule 16b-3 | 03/14/2024 |
11 | Surgery Partners Upgraded at StockNews.com - MarketBeat | 03/21/2024 |
12 | Surgery Partners plans 600 million senior notes offer | 03/26/2024 |
13 | Surgery Partners, Inc. Revenue Breakdown NASDAQSGRY TradingView - TradingView | 04/04/2024 |
14 | SGRY vs. DOCS Which Stock Should Value Investors Buy Now | 04/11/2024 |
15 | Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details | 04/18/2024 |
| Begin Period Cash Flow | 282.9 M |
Surgery |
Surgery Partners Relative Risk vs. Return Landscape
If you would invest 3,223 in Surgery Partners on January 20, 2024 and sell it today you would lose (881.00) from holding Surgery Partners or give up 27.33% of portfolio value over 90 days. Surgery Partners is currently does not generate positive expected returns and assumes 2.6171% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Surgery, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Surgery Partners Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Surgery Partners' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Surgery Partners, and traders can use it to determine the average amount a Surgery Partners' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1802
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SGRY |
Estimated Market Risk
| 2.62 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Surgery Partners is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Surgery Partners by adding Surgery Partners to a well-diversified portfolio.
Surgery Partners Fundamentals Growth
Surgery Stock prices reflect investors' perceptions of the future prospects and financial health of Surgery Partners, and Surgery Partners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Surgery Stock performance.
| Return On Equity | 0.0407 | ||||
| Return On Asset | 0.0383 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 7.34 B | ||||
| Shares Outstanding | 126.61 M | ||||
| Price To Earning | 61.84 X | ||||
| Price To Book | 1.68 X | ||||
| Price To Sales | 1.22 X | ||||
| Revenue | 2.74 B | ||||
| Gross Profit | 574.9 M | ||||
| EBITDA | 526.6 M | ||||
| Net Income | (11.9 M) | ||||
| Cash And Equivalents | 227.4 M | ||||
| Cash Per Share | 2.58 X | ||||
| Total Debt | 3.06 B | ||||
| Debt To Equity | 1.44 % | ||||
| Current Ratio | 1.51 X | ||||
| Book Value Per Share | 15.79 X | ||||
| Cash Flow From Operations | 293.8 M | ||||
| Earnings Per Share | (0.09) X | ||||
| Market Capitalization | 2.97 B | ||||
| Total Asset | 7.02 B | ||||
| Retained Earnings | (569.2 M) | ||||
| Working Capital | 372 M | ||||
| Current Asset | 310.96 M | ||||
| Current Liabilities | 181.29 M | ||||
About Surgery Partners Performance
To evaluate Surgery Partners Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Surgery Partners generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Surgery Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Surgery Partners market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Surgery's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 12.40 | 16.28 | |
| Return On Tangible Assets | (0) | (0) | |
| Return On Capital Employed | 0.06 | 0.07 | |
| Return On Assets | (0) | (0) | |
| Return On Equity | (0.01) | (0.01) |
Things to note about Surgery Partners performance evaluation
Checking the ongoing alerts about Surgery Partners for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Surgery Partners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Surgery Partners generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 2.74 B. Net Loss for the year was (11.9 M) with profit before overhead, payroll, taxes, and interest of 574.9 M. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from benzinga.com: Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details |
- Analyzing Surgery Partners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Surgery Partners' stock is overvalued or undervalued compared to its peers.
- Examining Surgery Partners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Surgery Partners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Surgery Partners' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Surgery Partners' stock. These opinions can provide insight into Surgery Partners' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Surgery Partners. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Surgery Stock please use our How to Invest in Surgery Partners guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Surgery Stock analysis
When running Surgery Partners' price analysis, check to measure Surgery Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgery Partners is operating at the current time. Most of Surgery Partners' value examination focuses on studying past and present price action to predict the probability of Surgery Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgery Partners' price. Additionally, you may evaluate how the addition of Surgery Partners to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Surgery Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Surgery Partners. If investors know Surgery will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Surgery Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share 21.839 | Quarterly Revenue Growth 0.04 | Return On Assets 0.0383 | Return On Equity 0.0407 |
The market value of Surgery Partners is measured differently than its book value, which is the value of Surgery that is recorded on the company's balance sheet. Investors also form their own opinion of Surgery Partners' value that differs from its market value or its book value, called intrinsic value, which is Surgery Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Surgery Partners' market value can be influenced by many factors that don't directly affect Surgery Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Surgery Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Surgery Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Surgery Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.